Real-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product
Debra Patt, M.D., M.P.H
Advertisement
Texas Oncology, affiliated with The US Oncology Network Medical Director of Healthcare Informatics, McKesson Specialty Health.
Articles by Debra Patt, M.D., M.P.H
Advertisement
Latest Updated Articles
- Outcomes Data: A Critical Insight for Market Access
Published: October 9th 2013 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
